IPOPLUS

2,930.3

-46.4 -1.56%

17 Jun 2026

NSE Listed · Healthcare

NGL Fine-Chem Limited (NGLFINE)

Volume: 34,30952W Range:9803,200
₹2,930.3 1.56%
Key Ratios
Updated 2h ago
Market Cap₹1,810 Cr
Current Price₹2,930.3
Previous Close₹2,976.7
High / Low (52w)₹3,200 / ₹980
Volume34,309
Avg Vol (1W)
Avg Vol (1M)
Stock P/E37.57
Book Value₹532.95
Dividend Yield0.06%
ROE15.74%
ROA6.78%
Revenue (TTM)
Revenue Growth
Profit Margin
Total Debt₹25 Cr
Shares Outstanding1 Cr
Face Value₹5
EPS (TTM)₹77.99
P/B5.5
Debt / Equity32.96
50 DMA₹2,481.28
200 DMA₹1,869.21
Day change-1.56%
Price Chart
2,930.3 188.18% · 1Y
30499941.0L
2025-06-17
2026-06-16

20-day avg volume: 34K shares

Pros
  • Healthy return on equity of 15.7%.
  • Revenue grew 36% YoY.
  • Net profit is growing year over year.
Quarterly Results
MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025
Revenue₹149 Cr₹128 Cr₹120 Cr₹104 Cr₹95 Cr
EBITDA₹24 Cr₹27 Cr₹19 Cr₹17 Cr₹5 Cr
Net Profit₹13 Cr₹16 Cr₹10 Cr₹9 Cr₹1 Cr
EPS21.8325.415.5814.960.88
Profit & Loss (Annual)
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Revenue₹501 Cr₹368 Cr₹334 Cr₹274 Cr
EBITDA₹87 Cr₹42 Cr₹67 Cr₹40 Cr
Net Profit₹48 Cr₹21 Cr₹41 Cr₹20 Cr
EPS34.1966.8833.1880.77
Balance Sheet
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Total Assets₹545 Cr₹433 Cr₹356 Cr₹287 Cr
Total Liabilities₹216 Cr₹151 Cr₹93 Cr₹65 Cr
Equity₹329 Cr₹282 Cr₹263 Cr₹223 Cr
Total Debt₹109 Cr₹77 Cr₹34 Cr₹32 Cr
Cash Flow
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Operating₹43 Cr₹32 Cr₹20 Cr₹35 Cr
Investing₹-71 Cr₹-70 Cr₹-27 Cr₹-27 Cr
Financing₹30 Cr₹37 Cr₹-1 Cr₹-1 Cr
Free Cash Flow₹-47 Cr₹-42 Cr₹-8 Cr₹4 Cr
Shareholding
Promoter 72.54% Institutions 0% Public 27.46%
About NGL Fine-Chem Limited

Healthcare · Drug Manufacturers - General

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search